La mesure continue du glucose : présent et avenir Mesure continue du glucose au long cours en 2012

The earliest continuous glucose monitoring (CGM) devices did not allow access to real-time blood glucose data. So, these devices were used to determine the glucose profile of patients in “real life” and as educational tools. In contrast, the latest real-time tools coupled or not with insulin pumps, provide to the patient glucose measurements in real time and allow setting different alerts. Thus, they become a new self-management tool available for patients with type 1 diabetes (T1D) under intensified insulinic treatment. Some long-term studies in a selected population of patients with uncontrolled T1D have shown improvement in glycemic control as measured by HbA1c when using the CGM. Although the characteristics of “responsive” patients have yet to be identified, the patient's ability to use the system of CGM on a near-daily basis (nearly 80% of the time) is a key point. The patient's specific training by a professional team with expertise in CGM is also important. This improvement in HbA1c was not associated with an increase or a reduction of time spent in hypoglycemia. So far there is no available data for the prevention of severe hypoglycemia with MCG. MCG is only at the begining of its development.